CN112553323A - Col1a1作为一种2型糖尿病的生物标志物及其应用 - Google Patents

Col1a1作为一种2型糖尿病的生物标志物及其应用 Download PDF

Info

Publication number
CN112553323A
CN112553323A CN202011561768.8A CN202011561768A CN112553323A CN 112553323 A CN112553323 A CN 112553323A CN 202011561768 A CN202011561768 A CN 202011561768A CN 112553323 A CN112553323 A CN 112553323A
Authority
CN
China
Prior art keywords
gly
pro
ala
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011561768.8A
Other languages
English (en)
Other versions
CN112553323B (zh
Inventor
赵超
陈逸晗
林国鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Agriculture and Forestry University
Original Assignee
Fujian Agriculture and Forestry University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Agriculture and Forestry University filed Critical Fujian Agriculture and Forestry University
Priority to CN202011561768.8A priority Critical patent/CN112553323B/zh
Publication of CN112553323A publication Critical patent/CN112553323A/zh
Application granted granted Critical
Publication of CN112553323B publication Critical patent/CN112553323B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Sustainable Development (AREA)
  • General Physics & Mathematics (AREA)

Abstract

本发明涉及一种新型Col1a1蛋白作为识别2型糖尿病的生物标记物的应用。本发明实验发现:Col1a1蛋白在2型糖尿病的大鼠组的空肠中表达量显著小于浒苔寡糖和正常大鼠组的空肠中表达量。基于液相质谱的串联质量标签(TMT)表明Col1a1作为ECM通路中影响最大的蛋白质受体。本发明进一步通过荧光定量、蛋白免疫印迹检验Col1a1蛋白在转录和蛋白水平的变化,证明Col1a1蛋白将是2型糖尿病的一个新的治疗靶点和生物标志物。

Description

COL1A1作为一种2型糖尿病的生物标志物及其应用
技术领域
本发明属于生物医药领域,涉及一种与糖尿病相关的生物标记物及其应用,具体的所述生物标记物为Col1a1。
背景技术
2型糖尿病(Type 2 diabetes)作为一种异质性、激素性和代谢性疾病,以高血糖和胰岛素抵抗为特征,当前正以极高的发病率在人群中蔓延。根据国际糖尿病联合会发布的报告统计,2019年全球约有4.51亿人被诊断为糖尿病,到2045年,这一数字将达到惊人的7.02亿人。随着近几十年来医疗及卫生技术手段的快速发展,以及各种药物治疗检测手段的不断完善,针对糖尿病的治疗已经取得可喜的进展。尽管如此,糖尿病及其并发症仍旧威胁着人们的身体健康。
高糖高脂饮食除了会诱发肥胖之外,也被一致认为是2型糖尿病发病的风险因素之一。与此同时也会诱发糖脂代谢紊乱、粥样动脉粥样硬化、心脏病及心血管疾病等其他严重并发症疾病的发生,这为2型糖尿病的治疗带来极大的难度。随着代谢组,蛋白质组及转录组学研究的深入,高通量测序技术的应用,人们发现了许多的糖尿病相关的生物标志物与其存在紧密关联。鉴于2型糖尿病发病因素的多样性,及治疗过程中所呈现出的指标及反应的多样性,当前生物标记物的发现与应用的程度远远不够,我们需要更多更好的生物标记物来针对性治疗各种诱发因素下的2型糖尿病。
蛋白质组学技术的飞速发展对于揭示2型糖尿病的基本机制和生物标志物至关重要。多种形式的载脂蛋白已被表征为2型糖尿病的靶向生物标志物。载脂蛋白A1是血浆中发现的高密度脂蛋白的主要成分。体内蛋白质水平的变化主要是由外部环境引起的,直接影响代谢途径,可以通过蛋白质组学进行分析。因此,蛋白质组学分析可以全面了解2型糖尿病中潜在的蛋白质生物标志物和机制。串联质量标签(TMT)作为化学标签被用于鉴定生物大分子,例如蛋白质和核酸。TMT标记的蛋白质组学分析也可以替代基于凝胶或抗体的传统测量方法,并已用于对糖尿病症状进行深入研究
α-1的I型胶原蛋白(Col1a1)是一种蛋白质,Col1a1编码I型胶原的主要成分,I型胶原是在包括软骨在内的大多数结缔组织中发现的纤维状胶原。它可以增强并支持人体的许多组织,包括软骨,骨骼,肌腱,皮肤和巩膜。过去的研究显示Col1a1的突变与人体的血管及器官破裂有关,如Ehlers-Danlos综合征,此外该基因的突变也易于导致成骨不全症及骨质疏松症的发生。
中国专利CN201611238922.1和CN201811625527.8中公开了Col1a1的应用及抑制剂的应用。该专利证实Col1a1的过表达会加剧肝脏如肝纤维化及其相关疾病的产生;证实Col1a1表达的抑制能够改善肝脏相关疾病的症状。以上专利是Col1a1与肝脏相关疾病的发现与运用,有别于该发明的内容,与此同时,尚未见Col1a1与肠道及2型糖尿病之间相关的报道。
发明内容
为针对性高糖高脂饮食所致的2型糖尿病的治疗,本发明的目的在于提供一种与高糖高脂饮食相关2型糖尿病的生物标记物及治疗靶点。
为实现本发明的目的,本发明提供了一种Col1a1蛋白在制备2型糖尿病生物标记物试剂中的应用。
Col1a1蛋白也可被称作胶原I型-α-1蛋白 (Collagen type I alpha 1 chain,Gene ID: 29393)。
串联质谱标签(TMT)能够对肠道的蛋白表达进行准确又灵敏的定量从而能准确识别2型糖尿病相关的生物标记物。
本发明前期收集2型糖尿病大鼠空肠以TMT蛋白质组学技术,检测了全部6810个蛋白质,结合生物信息学分析手段,按照蛋白质变化倍数比值为1.2 或0.83,P值低于0.05为阈值,筛选差异蛋白质。其中在模型组与正常组的比较中,265个蛋白质呈现差异表达。进一步地,通过差异蛋白网络互作图发现Col1a1在蛋白质的相互作用网络中处于功能网络节点数目较多的核心位置,并通过qPCR及Western bolt技术发现Col1a1表达异常降低,同时其空腹胰岛素、糖化血红蛋白、胰岛素信号通路PI3K及肠道内皮细胞稳态的相关基因MEK和ERK1/2的水平也出现了异常的表达。
所述蛋白和mRNA在糖尿病状态下空肠表达水平下降,与此同时其靶向miRNA(let-7g-5p)也通过高表达来抑制其mRNA的正常功能。
本发明的第一方面提供了一种试剂,所述试剂可以检测Col1a1的基因及miRNA表达水平。
进一步,所述试剂选自:
特异性扩增Col1a1基因的引物,引物序列如图所示。通过RT-QPCR进行检测判定。
本发明还提供了Col1a1蛋白作为糖尿病治疗靶点的应用。
本发明还提供了一种浒苔寡糖在制备治疗2型糖尿病药物中的应用,所述药物能够沉默let-7g-5p的表达水平以提高Col1a1的表达,并改善空腹胰岛素、糖化血红蛋白、PI3K信号通路以及肠道内皮细胞稳态的相关基因MEK和ERK1/2的水平。
一种如权利要求2所述浒苔寡糖的制备方法,其特征在于,包括以下步骤:按照1g:40mL的料液比将绿藻粉和水混合,在60℃、45 kHZ、200 W条件下超声波辅助提取1-2 h。4500 rpm离心5-10分钟后取上清液,按照1:4的体积比加入 95%乙醇醇沉过夜。离心取沉淀置于50℃干燥后,1 g:100mL的比例将其溶于水,在溶液中加入蛋白酶使酶活200 U/mL,30-40℃温度条件下酶解2 h后,100℃灭酶活20 min取上清液,再透析48 h后浓缩冻干得浒苔多糖。1%浒苔多糖水溶解液,加入硫酸直至溶液浓度为0.05 mol/L,100℃水浴酸解1.5 h后,冷却后加1.0 mol/L NaOH将溶液调至中性,按1:1的体积比加入95%乙醇溶液醇沉8-12h,后取上清液浓缩冻干,最终获得浒苔寡糖,特征产物的摩尔质量分布 <5000 Da(图6)。
本发明的优势在于:
本发明首次通过蛋白质组学的方式发现Col1a1蛋白的表达量与糖尿病存在相关性,并通过Western blot和qPCR验证该蛋白与基因的低表达会导致空腹胰岛素、糖化血红蛋白、胰岛素信号通路PI3K及肠道内皮细胞稳态的相关基因MEK和ERK1/2的表达水平异常。在进行浒苔寡糖给药后,大鼠空肠的Col1a1表达水平提高,伴随着空腹胰岛素、糖化血红蛋白、胰岛素信号通路PI3K及肠道内皮细胞稳态的相关基因MEK和ERK1/2的表达水平的改善。本发明为研究治疗高糖高脂饮食导致的2型糖尿病的提供了一个新的治疗靶点。
本发明发现与2型糖尿病相关联的Col1a1蛋白及基因,可用于诊断2型糖尿病,相比于传统的血糖及糖化血红蛋白检测手段,针对此特殊靶点的检测可为临床诊断和治疗提供新的参考价值。
附图说明
图1为本发明实施例1所述模型组大鼠与正常大鼠的Col1a1在蛋白质组学及生信技术分析下发现的差异表达;其中a, b图分别代表模型组比正常组(M/N),浒苔给药组比模型组(E/M),String网站构建空肠组织差异表达蛋白相互作用网络关联图,黄色节点和蓝色节点分别表示上下显著调节,节点大小代表比值的表达量的大小范围,线宽代表关联程度,(M/N,a);(E/M, b)。
图2为本发明实施例2所述Col1a1、miRNA(let-7g-5p)、PI3K、MEK和ERK1/2的蛋白及基因表达量变化情况;其中a、b、c分别为浒苔寡糖对2型糖尿病大鼠PI3K/MEK/ERK 1/2信号通路基因的mRNA 与蛋白表达水平的影响;c、d、e分别为浒苔寡糖对2型糖尿病大鼠目的基因mRNA与miRNA基因表达水平的影响浒苔寡糖对2型糖尿病大鼠目的基因蛋白表达水平的影响;(与正常组进行对比, P < 0.05: #, P < 0.01: ##;与模型组对比,P < 0.05: *,P < 0.01: **)。
图3为本发明实施例3所述浒苔寡糖给药后的模型组与给药组血糖值、胰岛素及糖化血红蛋白的变化情况;其中a为大鼠糖化血红蛋白变化情况;b为大鼠血清空腹胰岛素变化情况;c为大鼠空腹血糖变化情况。
图4为本发明实施例4所述的空肠HE染色后的电镜结果图。
图5为本发明浒苔寡糖的工艺流程图。
图6为浒苔寡糖通过凝胶渗透色谱(GPC)结合多角度激光光散射(MALLS)系统测得摩尔质量图;纵坐标为0.01-1×109
具体实施方式
实施例1:模型组大鼠与正常大鼠的Col1a1在蛋白质组学及生信技术分析下发现的差异表达
本发明通过TMT蛋白质组学分析,检测了全部6810个蛋白质,结合生信分析手段,将P值低于0.05设定为阈值判断显著性差异。其中在模型组与正常组的比较中,265个蛋白质呈现差异表达。进一步地,通过差异蛋白网络互作图发现Col1a1在蛋白质的相互作用网络中处于功能网络节点数目较多的核心位置,说明该蛋白可能在2型糖尿病中扮演着极其重要的角色,并可能参与了维持正常糖代谢功能的过程(图1)。
实施例2:蛋白及基因的差异表达
本发明通过qPCR及Western blot方法具体验证Col1a1、PI3K、MEK和ERK1/2的蛋白及基因在空肠上的表达量变化,发现模型组较之正常组发生显著低表达,而负责保守靶向调控Col1a1的miRNA(let-7g-5p)出现过表达的情况,而随后在给药组及模型组的比较上发现,Col1a1发生了显著的上调。同时, PI3K、MEK和ERK1/2,也相对发生了显著上调,而负责保守靶向调控Col1a1的miRNA(let-7g-5p)明显降低,这说明Col1a1在2型糖尿病中确实发挥了关键的作用(图2)。Col1a1的核苷酸序列和氨基酸序列分别如SEQ ID NO.1-2所示,PI3K的核苷酸序列和氨基酸序列分别如SEQ ID NO.3-4所示,MEK的核苷酸序列和氨基酸序列分别如SEQ ID NO.5-6所示;ERK1/2的核苷酸序列和氨基酸序列分别如SEQ ID NO.7-8所示;大鼠miRNA的碱基序列如SEQ ID NO.9所示。
具体实验方法如下:
(一)用Western Blot检测空肠的蛋白表达水平
(1)把组织剪切成细小的碎片;
(2)取适当量的Western及IP细胞裂解液(在使用前数分钟内加入PMSF,使PMSF的最终浓度为1 mM);
(3)按照20 mg组织加入200 μL裂解液的比例加入;
(4)用玻璃匀浆器进行匀浆,后置于冰浴,充分裂解60 min;
(5)12000 r/min,离心4 min后,取上清液,保存于-20℃冰箱。
BCA法测样品蛋白浓度。按照上样量目标值30 μg(如2 μg/μL,上样量15 μL),调整各组样本蛋白浓度一致(以PBS缓冲液稀释),将蛋白液装入1.5 mL离心管中,分别加入样品液四分之一体积的5×SDS蛋白上样缓冲液,使其终浓度为1×,封口膜封口后,将离心管置于沸水中煮沸5 min使蛋白质充分变性。后置于-20℃冰箱备用。
制备分离胶(8%)→无水乙醇液封→放置室温40 min等待分离胶凝固→倒掉无水乙醇后,用滤纸吸干残留的液体→加浓缩胶(5%)→插对应的梳子→等待20 min使浓缩胶凝固→加样15 μL(胶先放入RB电泳缓冲液中,再加样) →插好对应的电极(红对红,黑对黑)→先80 V跑电泳待溴酚蓝过了浓缩胶→调至120 V待溴酚蓝跑至底层即可关掉电极→转PVDF膜处理(先将PVDF膜放在甲醇中充分活化)→在TB转膜液中,夹板黑色面放底下,依次润湿泡沫、三层滤纸、胶、PVDF膜、三层滤纸、泡沫,按顺序叠放;转膜条件200 mA,2 h→置于摇床,用封闭液室温封闭30 min→加入一抗液稀释比例1:1000,4℃过夜孵育→置于摇床用TBST液洗脱PVDF膜,10 min/次,重复4次→加入二抗蛋白液稀释比例1:1000,37℃孵育40min →置于摇床用TBST液洗脱PVDF膜,10 min/次,重复4次→加入显色液A:B液,进行曝光成像。
(二)提取RNA
称取约0.1 g肝脏样品,放入液氮预冷的研钵,使用研杵不断研磨样品,直至磨成粉末。随后加入2 mL RNAiso plus裂解液试剂,完全覆盖肝脏样品,室温静置10 min,待样品融化后再用研杵继续研磨,直至样品呈透明状,随后分别转至2个1.5 mL的离心管中,37℃静置5 min后,使用高速离心机13500 rpm/min在4 ℃下离心5 min,取上清液重新转移至离心管中,加入五分之一裂解液体积的氯仿,剧烈振荡15 s乳化至无分相,再次室温静置5min。之后再采用相同的离心方法用离心15 min,取约200 µL上清液转至新的离心管中,再加入裂解液等体积的异丙醇,震荡均匀,37℃放置10 min。相同方法离心10 min后,弃上清液后缓慢加入1 mL 75%乙醇(-20 ℃事先预冷),上下颠倒,再用相同方法高速离心5 min,弃上清液后再用乙醇重复一次,随后室温晾干。取RNase free H2O溶解沉淀至体积为60uL,-80℃冰箱保存备用。
(三)反转录
根据带有gDNA Eraser的反转录试剂盒说明书对4.2.1提取成功的肝脏RNA进行逆转录,得到cDNA,根据实验需求适当稀释2-3倍,-80℃保存备用。
引物见下表1。
表1用于检测基因的引物
Figure DEST_PATH_IMAGE001
(四)PCR
将RNA反转录后得到的cDNA第一链作为模板, 设计引物。 利用宝日医生物技术(大连)有限公司的SYBR Green实时荧光定量PCR检测试剂盒, 检测目的基因的表达量。PCR扩增程序如下:25℃维持10s,一个循环;95℃维持30s,一个循环;95℃和60℃分别设定运行5s及31s,运行40个循环;最后熔解曲线分析,95℃,15s;60℃,30s;95℃,15s;一个循环。
实施例3:浒苔寡糖给药后的模型组与给药组血糖值、胰岛素及糖化血红蛋白的变化情况
本发明通过对模型组、给药组的空腹胰岛素和糖化血红蛋白来具体验证Col1a1下调对于这两者的影响,发现模型组因为Col1a1的下调导致空腹胰岛素和糖化血红蛋白含量分别发生了极显著的下调与上调作用,而在恢复Col1a1表达后,二者恢复了正常的水平值,说明Col1a1的抑制恶化了机体对于糖代谢的调节能力(图3)具体操作步骤如下:1.空腹血糖测定:通过浒苔寡糖每干预两周通过OMRON血糖仪检测空腹血糖值(FBG)水平;2. 收集大鼠的血液,室温静置2 h后,在3000 r/min,10 min,4℃条件下分离出血清,保存于冰箱-20℃。通过糖化血红蛋白(HBAC)和血清胰岛素(FINS)大鼠ELISA试剂盒测定大鼠的HBAC和FINS含量。
实施例4:空肠HE染色
本发明通过HE染色检测2型糖尿病大鼠空肠的变化情况,结果如图4所示。发现模型组空肠绒毛萎缩、水肿、断裂与大量浸润着炎症巨噬细胞。表明2型糖尿病会引起大鼠肠道黏膜病变。给药组无明显肠绒毛水肿,绒毛排列较为整齐,缺失断裂减少。说明Col1a1的正常表达与否可能会对空肠结构起到关键作用,进而调控正常糖代谢功能。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
实施例5:制备浒苔寡糖(EPO)的工艺路线(图5)
称取100 g绿藻粉,按照1:40的料液比将其溶解。在60℃、45 kHZ, 200 W功率条件下超声波辅助提取1h,重复1h。用纱布过滤,将滤液离心。设置离心机为4500 rpm,十分钟后取上清液,抽滤得到滤液,再将其旋转蒸发浓缩至500 ml,按照1:4的比例加入2000 ml 95%乙醇醇沉过夜。再将其离心,取沉淀置于50℃烘箱烘干。按照1:100的比例将其溶于水,再放至电动搅拌机中助溶,持续约90 min。在溶液中加入蛋白酶使酶活200 U/mL,在最适温度中酶解2h。酶解结束后,将溶液放置于100℃水浴锅中,灭活20 min,再离心,去沉淀取上清液。将取得液体透析48 h,浓缩至10-20ml,冻干得到绿藻浒苔多糖。
取15 g绿藻浒苔多糖用水溶解成1%多糖溶液,加入浓硫酸,直至溶液浓度为0.05mol/L,放入100℃水浴锅中酸解1.5 h后,静置冷却。冷却后加1.0 mol/L NaOH将溶液调至中性,再浓缩溶液,按1:1的比例加入乙醇溶液醇沉8h以上,后取上清液浓缩冻干,最终取得粉末状物质为浒苔寡糖(EPO)。
SEQUENCE LISTING
<110> 福建农林大学
<120> COL1A1作为一种2型糖尿病的生物标志物及其应用
<130> 25
<160> 25
<170> PatentIn version 3.3
<210> 1
<211> 4362
<212> DNA
<213> 人工序列
<400> 1
atgttcagct ttgtggacct ccggctcctg ctcctcttag gggccactgc cctcctgacg 60
catggccaag aagacatccc tgaagtcagc tgcatacaca atggcctaag ggtccctaat 120
ggtgagacgt ggaaacctga tgtatgcttg atctgtatct gccacaatgg cacggctgtg 180
tgcgatggcg tgctatgcaa agaagacttg gactgtccca acccccaaaa acgggagggc 240
gagtgctgtc ctttctgccc agaagaatat gtatcaccag acgcagaagt cataggagtc 300
gagggaccca agggagaccc tggcccccaa ggcccacggg gacctgttgg cccccctgga 360
caagatggca tccctggaca gcctggactt cctggtcctc ctggtccccc cggccccccc 420
ggaccccctg gtcttggagg aaactttgct tcccagatgt cctatggcta tgatgagaaa 480
tcagctggag tttccgtgcc tggccccatg ggtccttctg gtcctcgtgg tctccctggc 540
ccccctggtg cacctggtcc tcaaggtttc caaggccccc ctggtgaacc tggcgagcct 600
ggcgcttcag gtccaatggg tccccgaggt ccccctggcc ctcctggcaa gaacggagat 660
gatggggaag ctggtaagcc tggccgccct ggtgagcgtg gacctcctgg acctcagggt 720
gctcgtggat tgcctggaac agctggcctc cccggaatga agggacacag aggtttcagt 780
ggtttggatg gtgccaaagg agatactggt cctgctggtc ctaagggaga gcctggcagt 840
cctggtgaaa atggagctcc cggccagatg ggtccccgag gtctgcctgg tgagagaggt 900
cgccctggac cccctggcag tgctggtgct cgtggtaacg atggtgctgt cggtgcagct 960
gggccccccg gtcccaccgg ccctactggc cctcctggct tccctggtgc agctggtgct 1020
aagggtgaag ctggtcccca gggagcccga ggctctgaag gtccccaggg tgtgcgtggt 1080
gagcccggac cccctggccc tgctggtgct gctggtcctg ctggaaaccc tggtgctgat 1140
ggacaacctg gtgctaaagg tgccaatggt gctcctggta ttgctggtgc tcctggcttc 1200
cctggtgccc gaggcccctc tggacctcag ggccccagcg gcgctcctgg tcccaaaggc 1260
aacagtggtg aacctggtgc ccctggcaac aaaggagaca ctggtgccaa aggagaaccc 1320
ggccctgctg gagttcaagg tccccctggc cctgctggag aagaaggaaa acgaggagcc 1380
cgtggtgagc ctggacctag cggcctgccc ggacctcctg gcgagcgcgg tggacctggt 1440
agccgtggtt tccctggtgc tgatggtgtt gctggcccca agggtcctgc tggtgaacgt 1500
ggttctcctg gccctgctgg tcccaaaggt tctcctggtg aagctggtcg ccctggtgaa 1560
gctggtctcc ctggtgccaa gggtctcact ggcagtcctg gcagccctgg tcctgatggc 1620
aaaaccggcc cccctggtcc cgctggtcaa gatggtcgcc ctggacccgc aggtcctcct 1680
ggagcccgtg gacaggctgg tgtgatggga ttccctggac ctaagggtac tgctggagaa 1740
cctggaaagg ctggagaacg aggtgtcccc ggaccccctg gcgctgttgg tcccgctggc 1800
aaagatggcg aagctggagc tcaaggagcc cccggccctg ctggtcctgc tggtgagaga 1860
ggtgaacaag gtcccgctgg ctcccctgga ttccagggtc ttcctggtcc cgctggtcct 1920
cctggtgaag caggcaagcc tggtgaacag ggtgttcctg gagaccttgg tgcccctgga 1980
ccctctggcg caagaggcga gagaggtttc cctggtgaac gtggtgtaca aggtccccca 2040
ggtcctgctg gtccccgagg aaacaatggt gcccccggca acgatggtgc caagggtgat 2100
actggtgccc ccggagctcc tggtagccag ggtgcccccg gtcttcaggg aatgcctggt 2160
gaacgtggtg cagctggtct tccaggtcct aagggtgaca gaggtgatgc tggtcccaaa 2220
ggtgctgatg gttctcctgg caaagatggc gtccgtggtc tgactggtcc cattggtcct 2280
cctggccctg ctggtgcccc tggtgacaag ggtgaaactg gtcccagtgg tcctgctggc 2340
cccaccggag cccgtggtgc ccccggagac cgtggtgagc ctggtccccc tggtcctgct 2400
ggcttcgctg gcccccctgg tgctgatggc caacctggtg cgaaaggtga acctggtgat 2460
actggtgtga aaggtgacgc tggtcctcct ggccctgctg gtcccgctgg accccctggc 2520
cccattggta acgttggtgc tcctggaccc aaaggttctc gtggtgctgc tggtccccct 2580
ggtgctactg gtttccctgg tgctgctggt cgtgttggtc cccctggtcc ctctggaaat 2640
gctggacccc ctggccctcc cggtcccgtt ggcaaagaag ggggcaaagg tccccgtggt 2700
gagactggtc ccgctggacg tcctggtgaa gttggtcccc caggtccccc tggccctgct 2760
ggtgagaaag gatctcctgg tgctgatgga cctgctggct ctcctggtac ccctggacct 2820
cagggtattg ctggacagcg tggtgtggtc ggtcttcccg gtcagagagg agaaagaggc 2880
ttccctggtc ttcctggacc ctctggtgaa cccggcaaac aaggtccttc tggagcaagt 2940
ggtgaacgtg gtccccctgg ccctatgggc ccccctggat tggctggccc ccctggtgaa 3000
tctggtcgtg agggatcccc tggtgctgaa ggctcccctg gaagagatgg tgctcctggt 3060
gccaagggtg accgtggtga gactggccct gctggccccc ctggtgctcc tggtgctcct 3120
ggtgctcccg gccctgttgg tcctgctggc aagaatggcg accgtggtga gactggtcct 3180
gctggtcctg ctggtcccat tggccctgct ggtgcccgtg gtcctgctgg accccaaggc 3240
ccccgtggtg acaagggtga gacaggcgaa caaggtgaca gaggcataaa gggtcatcgt 3300
ggcttctctg gtctccaggg tcctcctggc tctcctggct ctcctggtga acaaggcccc 3360
tctggagctt ctggtcctgc aggtccccgg ggtccccctg gctctgctgg ttctcctggc 3420
aaagatggac tcaacggtct ccctggcccc attggtcccc ctggtcctcg aggtcgcact 3480
ggcgatagtg gtcctgctgg tccccccgga cctcctggac cccctggccc tcccggtcct 3540
cccagcggtg gttatgactt cagcttcctg cctcagccac ctcaagagaa gtctcaagat 3600
ggtggccgtt actaccgggc cgatgatgcc aacgtggtcc gtgaccgtga ccttgaggtg 3660
gacactaccc tcaagagcct gagccagcag attgagaaca tccgcagccc tgagggcagc 3720
cgcaagaacc ccgcccgcac atgccgtgac ctcaagatgt gccactctga ctggaagagc 3780
ggagagtact ggatcgaccc taaccaaggc tgcaacctgg atgccatcaa ggtctactgc 3840
aacatggaga caggtcagac ctgtgtgttc cccactcagc cctctgtgcc tcagaagaac 3900
tggtacatca gcccaaaccc caaggagaag aagcatgtct ggtttggaga gagcatgacc 3960
gatggattcc agttcgagta tggaagcgaa ggttccgatc ctgccgatgt cgctatccag 4020
ctgaccttcc tgcgcctgat gtccaccgag gcctcccaga acatcaccta tcactgcaag 4080
aacagcgtag cctacatgga ccaacagact ggcaacctca agaagtccct gctcctccag 4140
ggctccaacg agatcgagct caggggcgaa ggcaacagtc gattcaccta cagcacgctt 4200
gtggatggct gcacgagtca caccggaact tggggcaaga cagtcatcga atacaaaacc 4260
accaagacct cccgcctgcc catcatcgat gtggctccct tggacattgg tgccccagac 4320
caggaattcg gaatggacat tggccctgcc tgcttcgtgt aa 4362
<210> 2
<211> 1453
<212> PRT
<213> 人工序列
<400> 2
Met Phe Ser Phe Val Asp Leu Arg Leu Leu Leu Leu Leu Gly Ala Thr
1 5 10 15
Ala Leu Leu Thr His Gly Gln Glu Asp Ile Pro Glu Val Ser Cys Ile
20 25 30
His Asn Gly Leu Arg Val Pro Asn Gly Glu Thr Trp Lys Pro Asp Val
35 40 45
Cys Leu Ile Cys Ile Cys His Asn Gly Thr Ala Val Cys Asp Gly Val
50 55 60
Leu Cys Lys Glu Asp Leu Asp Cys Pro Asn Pro Gln Lys Arg Glu Gly
65 70 75 80
Glu Cys Cys Pro Phe Cys Pro Glu Glu Tyr Val Ser Pro Asp Ala Glu
85 90 95
Val Ile Gly Val Glu Gly Pro Lys Gly Asp Pro Gly Pro Gln Gly Pro
100 105 110
Arg Gly Pro Val Gly Pro Pro Gly Gln Asp Gly Ile Pro Gly Gln Pro
115 120 125
Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
130 135 140
Leu Gly Gly Asn Phe Ala Ser Gln Met Ser Tyr Gly Tyr Asp Glu Lys
145 150 155 160
Ser Ala Gly Val Ser Val Pro Gly Pro Met Gly Pro Ser Gly Pro Arg
165 170 175
Gly Leu Pro Gly Pro Pro Gly Ala Pro Gly Pro Gln Gly Phe Gln Gly
180 185 190
Pro Pro Gly Glu Pro Gly Glu Pro Gly Ala Ser Gly Pro Met Gly Pro
195 200 205
Arg Gly Pro Pro Gly Pro Pro Gly Lys Asn Gly Asp Asp Gly Glu Ala
210 215 220
Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly
225 230 235 240
Ala Arg Gly Leu Pro Gly Thr Ala Gly Leu Pro Gly Met Lys Gly His
245 250 255
Arg Gly Phe Ser Gly Leu Asp Gly Ala Lys Gly Asp Thr Gly Pro Ala
260 265 270
Gly Pro Lys Gly Glu Pro Gly Ser Pro Gly Glu Asn Gly Ala Pro Gly
275 280 285
Gln Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly Arg Pro Gly Pro
290 295 300
Pro Gly Ser Ala Gly Ala Arg Gly Asn Asp Gly Ala Val Gly Ala Ala
305 310 315 320
Gly Pro Pro Gly Pro Thr Gly Pro Thr Gly Pro Pro Gly Phe Pro Gly
325 330 335
Ala Ala Gly Ala Lys Gly Glu Ala Gly Pro Gln Gly Ala Arg Gly Ser
340 345 350
Glu Gly Pro Gln Gly Val Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala
355 360 365
Gly Ala Ala Gly Pro Ala Gly Asn Pro Gly Ala Asp Gly Gln Pro Gly
370 375 380
Ala Lys Gly Ala Asn Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly Phe
385 390 395 400
Pro Gly Ala Arg Gly Pro Ser Gly Pro Gln Gly Pro Ser Gly Ala Pro
405 410 415
Gly Pro Lys Gly Asn Ser Gly Glu Pro Gly Ala Pro Gly Asn Lys Gly
420 425 430
Asp Thr Gly Ala Lys Gly Glu Pro Gly Pro Ala Gly Val Gln Gly Pro
435 440 445
Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu Pro
450 455 460
Gly Pro Ser Gly Leu Pro Gly Pro Pro Gly Glu Arg Gly Gly Pro Gly
465 470 475 480
Ser Arg Gly Phe Pro Gly Ala Asp Gly Val Ala Gly Pro Lys Gly Pro
485 490 495
Ala Gly Glu Arg Gly Ser Pro Gly Pro Ala Gly Pro Lys Gly Ser Pro
500 505 510
Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro Gly Ala Lys Gly
515 520 525
Leu Thr Gly Ser Pro Gly Ser Pro Gly Pro Asp Gly Lys Thr Gly Pro
530 535 540
Pro Gly Pro Ala Gly Gln Asp Gly Arg Pro Gly Pro Ala Gly Pro Pro
545 550 555 560
Gly Ala Arg Gly Gln Ala Gly Val Met Gly Phe Pro Gly Pro Lys Gly
565 570 575
Thr Ala Gly Glu Pro Gly Lys Ala Gly Glu Arg Gly Val Pro Gly Pro
580 585 590
Pro Gly Ala Val Gly Pro Ala Gly Lys Asp Gly Glu Ala Gly Ala Gln
595 600 605
Gly Ala Pro Gly Pro Ala Gly Pro Ala Gly Glu Arg Gly Glu Gln Gly
610 615 620
Pro Ala Gly Ser Pro Gly Phe Gln Gly Leu Pro Gly Pro Ala Gly Pro
625 630 635 640
Pro Gly Glu Ala Gly Lys Pro Gly Glu Gln Gly Val Pro Gly Asp Leu
645 650 655
Gly Ala Pro Gly Pro Ser Gly Ala Arg Gly Glu Arg Gly Phe Pro Gly
660 665 670
Glu Arg Gly Val Gln Gly Pro Pro Gly Pro Ala Gly Pro Arg Gly Asn
675 680 685
Asn Gly Ala Pro Gly Asn Asp Gly Ala Lys Gly Asp Thr Gly Ala Pro
690 695 700
Gly Ala Pro Gly Ser Gln Gly Ala Pro Gly Leu Gln Gly Met Pro Gly
705 710 715 720
Glu Arg Gly Ala Ala Gly Leu Pro Gly Pro Lys Gly Asp Arg Gly Asp
725 730 735
Ala Gly Pro Lys Gly Ala Asp Gly Ser Pro Gly Lys Asp Gly Val Arg
740 745 750
Gly Leu Thr Gly Pro Ile Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly
755 760 765
Asp Lys Gly Glu Thr Gly Pro Ser Gly Pro Ala Gly Pro Thr Gly Ala
770 775 780
Arg Gly Ala Pro Gly Asp Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala
785 790 795 800
Gly Phe Ala Gly Pro Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly
805 810 815
Glu Pro Gly Asp Thr Gly Val Lys Gly Asp Ala Gly Pro Pro Gly Pro
820 825 830
Ala Gly Pro Ala Gly Pro Pro Gly Pro Ile Gly Asn Val Gly Ala Pro
835 840 845
Gly Pro Lys Gly Ser Arg Gly Ala Ala Gly Pro Pro Gly Ala Thr Gly
850 855 860
Phe Pro Gly Ala Ala Gly Arg Val Gly Pro Pro Gly Pro Ser Gly Asn
865 870 875 880
Ala Gly Pro Pro Gly Pro Pro Gly Pro Val Gly Lys Glu Gly Gly Lys
885 890 895
Gly Pro Arg Gly Glu Thr Gly Pro Ala Gly Arg Pro Gly Glu Val Gly
900 905 910
Pro Pro Gly Pro Pro Gly Pro Ala Gly Glu Lys Gly Ser Pro Gly Ala
915 920 925
Asp Gly Pro Ala Gly Ser Pro Gly Thr Pro Gly Pro Gln Gly Ile Ala
930 935 940
Gly Gln Arg Gly Val Val Gly Leu Pro Gly Gln Arg Gly Glu Arg Gly
945 950 955 960
Phe Pro Gly Leu Pro Gly Pro Ser Gly Glu Pro Gly Lys Gln Gly Pro
965 970 975
Ser Gly Ala Ser Gly Glu Arg Gly Pro Pro Gly Pro Met Gly Pro Pro
980 985 990
Gly Leu Ala Gly Pro Pro Gly Glu Ser Gly Arg Glu Gly Ser Pro Gly
995 1000 1005
Ala Glu Gly Ser Pro Gly Arg Asp Gly Ala Pro Gly Ala Lys Gly
1010 1015 1020
Asp Arg Gly Glu Thr Gly Pro Ala Gly Pro Pro Gly Ala Pro Gly
1025 1030 1035
Ala Pro Gly Ala Pro Gly Pro Val Gly Pro Ala Gly Lys Asn Gly
1040 1045 1050
Asp Arg Gly Glu Thr Gly Pro Ala Gly Pro Ala Gly Pro Ile Gly
1055 1060 1065
Pro Ala Gly Ala Arg Gly Pro Ala Gly Pro Gln Gly Pro Arg Gly
1070 1075 1080
Asp Lys Gly Glu Thr Gly Glu Gln Gly Asp Arg Gly Ile Lys Gly
1085 1090 1095
His Arg Gly Phe Ser Gly Leu Gln Gly Pro Pro Gly Ser Pro Gly
1100 1105 1110
Ser Pro Gly Glu Gln Gly Pro Ser Gly Ala Ser Gly Pro Ala Gly
1115 1120 1125
Pro Arg Gly Pro Pro Gly Ser Ala Gly Ser Pro Gly Lys Asp Gly
1130 1135 1140
Leu Asn Gly Leu Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg Gly
1145 1150 1155
Arg Thr Gly Asp Ser Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly
1160 1165 1170
Pro Pro Gly Pro Pro Gly Pro Pro Ser Gly Gly Tyr Asp Phe Ser
1175 1180 1185
Phe Leu Pro Gln Pro Pro Gln Glu Lys Ser Gln Asp Gly Gly Arg
1190 1195 1200
Tyr Tyr Arg Ala Asp Asp Ala Asn Val Val Arg Asp Arg Asp Leu
1205 1210 1215
Glu Val Asp Thr Thr Leu Lys Ser Leu Ser Gln Gln Ile Glu Asn
1220 1225 1230
Ile Arg Ser Pro Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys
1235 1240 1245
Arg Asp Leu Lys Met Cys His Ser Asp Trp Lys Ser Gly Glu Tyr
1250 1255 1260
Trp Ile Asp Pro Asn Gln Gly Cys Asn Leu Asp Ala Ile Lys Val
1265 1270 1275
Tyr Cys Asn Met Glu Thr Gly Gln Thr Cys Val Phe Pro Thr Gln
1280 1285 1290
Pro Ser Val Pro Gln Lys Asn Trp Tyr Ile Ser Pro Asn Pro Lys
1295 1300 1305
Glu Lys Lys His Val Trp Phe Gly Glu Ser Met Thr Asp Gly Phe
1310 1315 1320
Gln Phe Glu Tyr Gly Ser Glu Gly Ser Asp Pro Ala Asp Val Ala
1325 1330 1335
Ile Gln Leu Thr Phe Leu Arg Leu Met Ser Thr Glu Ala Ser Gln
1340 1345 1350
Asn Ile Thr Tyr His Cys Lys Asn Ser Val Ala Tyr Met Asp Gln
1355 1360 1365
Gln Thr Gly Asn Leu Lys Lys Ser Leu Leu Leu Gln Gly Ser Asn
1370 1375 1380
Glu Ile Glu Leu Arg Gly Glu Gly Asn Ser Arg Phe Thr Tyr Ser
1385 1390 1395
Thr Leu Val Asp Gly Cys Thr Ser His Thr Gly Thr Trp Gly Lys
1400 1405 1410
Thr Val Ile Glu Tyr Lys Thr Thr Lys Thr Ser Arg Leu Pro Ile
1415 1420 1425
Ile Asp Val Ala Pro Leu Asp Ile Gly Ala Pro Asp Gln Glu Phe
1430 1435 1440
Gly Met Asp Ile Gly Pro Ala Cys Phe Val
1445 1450
<210> 3
<211> 2175
<212> DNA
<213> 人工序列
<220>
<221> misc_feature
<222> (1098)..(1098)
<223> n is a, c, g, or t
<400> 3
atgagcgcag aggggtacca gtacagagcg ctgtatgact acaaaaagga acgagaggaa 60
gacatcgacc tacacttggg ggacatcctg actgtgaata aaggctcctt agtggcactt 120
ggattcagtg atggccagga agcccggcca gaagatattg gctggttaaa tggttacaat 180
gaaactactg gggagagggg agactttcca ggaacttatg ttgagtacat tggaaggaaa 240
agaatttcac cccccactcc taagccacgg ccccctcgac ctcttcctgt agcacccggt 300
tcttcaaaaa ctgaagcaga cactgagcaa ccagtgttga cccttcctga tctggccgag 360
cagtttgccc ctcctgatgt tgccccgcct ctccttataa agctcctgga agccattgag 420
aagaaaggac tggaatgttc aactctatac agaacacaga gctccagcaa ccctgcagag 480
ttacgacagc ttcttgattg tgatcccccc tcagtggact tggatgtgtt cgatgaacac 540
gttttagcag atgctttcaa acgctatctc gccgacttac caaatcctgt cattccagta 600
gctgtttaca atgagatgat gtctttagcc caagaagtac caagctccga agactacatc 660
cagctgttga agaagctcat taggtcgcct aatatacctc atcagtattg gcttacgctc 720
cagtatttgc tcaagcactt cttcaagctc tctcaagcct ccagcaagaa ccttctgaat 780
gcaagagccc tctctgaaat tttcagccac gtgcttttca gattcccagc agccagctct 840
gataatactg aacacctcat aaaagcggta gagcttttaa tctcagcgga gtggagtgag 900
cgacagccag caccagcact gccccctaaa ccacccaagc ccacttctat agccaacaac 960
agcatgaaca acaatatgtc cttacaggat gctgaatggt actggggaga tatctcaagg 1020
gaagaagtaa atgaaaaact ccgagacact gctgatggga cctttctggt acgagatgca 1080
tccactaaaa tgcacggnga ctacactctc acactaagga aaggaggaaa taacaaatta 1140
atcaaaatct ttcaccgaga tgggaaatac ggtttctctg atccattaac cttcaactct 1200
gtggttgaat taataaacca ctaccggaat gagtccttag ctcagtacaa tcccaagctg 1260
gatgtgaagt tactctaccc agtgtctaaa taccagcagg atcaagttgt caaagaagat 1320
aatattgaag ctgtggggaa aaaattacat gaatataata ctcaatttca agaaaaaagt 1380
cgggaatatg atagattata tgaggaatac actcgtactt cccaggaaat acagatgaaa 1440
agaacagcta tcgaagcatt taatgacacc ataaaaatat tcgaagagca gtgccacccc 1500
caggagcggt acagcaaaga ctacatagag aagtttaaac gcgaaggcaa cgagaaggaa 1560
attcaaagga taatgcataa tcacgataag ctgaagtctc ggatcagcga gatcatcgac 1620
agcaggagga gactggagga agacttgaag aagcaggcag ccgagtatcg cgagatcgac 1680
aagcgcatga atagcattaa gccggacctc attcagctga gaaagacaag agatcaatac 1740
ttgatgtggc tgacgcagaa aggggtccgg cagaagaagc tgaacgaatg gttgggaaac 1800
gaaaacacag aagaccaata ctcactggta gacgatgacg aggatttgcc ccaccatgat 1860
gagaagacgt ggaatgtggg gagcagcaac cgaaacaaag ccgagaacct attgcgaggg 1920
aaacgagatg gcactttcct ggtccgggag agcagtaagc agggctgcta tgcctgctct 1980
gtagtggtag atggcgaagt caaacattgc gtcatcaaca agactgccac cggctatggc 2040
ttcgccgagc cctacaacct gtacagctcc ctgaaagagc tggtgctaca ttaccaacac 2100
acctccctgg tgcagcacaa tgactccctc aatgtcacac tagcataccc agtatatgca 2160
caacagaggc gatga 2175
<210> 4
<211> 724
<212> PRT
<213> 人工序列
<400> 4
Met Ser Ala Glu Gly Tyr Gln Tyr Arg Ala Leu Tyr Asp Tyr Lys Lys
1 5 10 15
Glu Arg Glu Glu Asp Ile Asp Leu His Leu Gly Asp Ile Leu Thr Val
20 25 30
Asn Lys Gly Ser Leu Val Ala Leu Gly Phe Ser Asp Gly Gln Glu Ala
35 40 45
Arg Pro Glu Asp Ile Gly Trp Leu Asn Gly Tyr Asn Glu Thr Thr Gly
50 55 60
Glu Arg Gly Asp Phe Pro Gly Thr Tyr Val Glu Tyr Ile Gly Arg Lys
65 70 75 80
Arg Ile Ser Pro Pro Thr Pro Lys Pro Arg Pro Pro Arg Pro Leu Pro
85 90 95
Val Ala Pro Gly Ser Ser Lys Thr Glu Ala Asp Thr Glu Gln Pro Val
100 105 110
Leu Thr Leu Pro Asp Leu Ala Glu Gln Phe Ala Pro Pro Asp Val Ala
115 120 125
Pro Pro Leu Leu Ile Lys Leu Leu Glu Ala Ile Glu Lys Lys Gly Leu
130 135 140
Glu Cys Ser Thr Leu Tyr Arg Thr Gln Ser Ser Ser Asn Pro Ala Glu
145 150 155 160
Leu Arg Gln Leu Leu Asp Cys Asp Pro Pro Ser Val Asp Leu Asp Val
165 170 175
Phe Asp Glu His Val Leu Ala Asp Ala Phe Lys Arg Tyr Leu Ala Asp
180 185 190
Leu Pro Asn Pro Val Ile Pro Val Ala Val Tyr Asn Glu Met Met Ser
195 200 205
Leu Ala Gln Glu Val Pro Ser Ser Glu Asp Tyr Ile Gln Leu Leu Lys
210 215 220
Lys Leu Ile Arg Ser Pro Asn Ile Pro His Gln Tyr Trp Leu Thr Leu
225 230 235 240
Gln Tyr Leu Leu Lys His Phe Phe Lys Leu Ser Gln Ala Ser Ser Lys
245 250 255
Asn Leu Leu Asn Ala Arg Ala Leu Ser Glu Ile Phe Ser His Val Leu
260 265 270
Phe Arg Phe Pro Ala Ala Ser Ser Asp Asn Thr Glu His Leu Ile Lys
275 280 285
Ala Val Glu Leu Leu Ile Ser Ala Glu Trp Ser Glu Arg Gln Pro Ala
290 295 300
Pro Ala Leu Pro Pro Lys Pro Pro Lys Pro Thr Ser Ile Ala Asn Asn
305 310 315 320
Ser Met Asn Asn Asn Met Ser Leu Gln Asp Ala Glu Trp Tyr Trp Gly
325 330 335
Asp Ile Ser Arg Glu Glu Val Asn Glu Lys Leu Arg Asp Thr Ala Asp
340 345 350
Gly Thr Phe Leu Val Arg Asp Ala Ser Thr Lys Met His Gly Asp Tyr
355 360 365
Thr Leu Thr Leu Arg Lys Gly Gly Asn Asn Lys Leu Ile Lys Ile Phe
370 375 380
His Arg Asp Gly Lys Tyr Gly Phe Ser Asp Pro Leu Thr Phe Asn Ser
385 390 395 400
Val Val Glu Leu Ile Asn His Tyr Arg Asn Glu Ser Leu Ala Gln Tyr
405 410 415
Asn Pro Lys Leu Asp Val Lys Leu Leu Tyr Pro Val Ser Lys Tyr Gln
420 425 430
Gln Asp Gln Val Val Lys Glu Asp Asn Ile Glu Ala Val Gly Lys Lys
435 440 445
Leu His Glu Tyr Asn Thr Gln Phe Gln Glu Lys Ser Arg Glu Tyr Asp
450 455 460
Arg Leu Tyr Glu Glu Tyr Thr Arg Thr Ser Gln Glu Ile Gln Met Lys
465 470 475 480
Arg Thr Ala Ile Glu Ala Phe Asn Asp Thr Ile Lys Ile Phe Glu Glu
485 490 495
Gln Cys His Pro Gln Glu Arg Tyr Ser Lys Asp Tyr Ile Glu Lys Phe
500 505 510
Lys Arg Glu Gly Asn Glu Lys Glu Ile Gln Arg Ile Met His Asn His
515 520 525
Asp Lys Leu Lys Ser Arg Ile Ser Glu Ile Ile Asp Ser Arg Arg Arg
530 535 540
Leu Glu Glu Asp Leu Lys Lys Gln Ala Ala Glu Tyr Arg Glu Ile Asp
545 550 555 560
Lys Arg Met Asn Ser Ile Lys Pro Asp Leu Ile Gln Leu Arg Lys Thr
565 570 575
Arg Asp Gln Tyr Leu Met Trp Leu Thr Gln Lys Gly Val Arg Gln Lys
580 585 590
Lys Leu Asn Glu Trp Leu Gly Asn Glu Asn Thr Glu Asp Gln Tyr Ser
595 600 605
Leu Val Asp Asp Asp Glu Asp Leu Pro His His Asp Glu Lys Thr Trp
610 615 620
Asn Val Gly Ser Ser Asn Arg Asn Lys Ala Glu Asn Leu Leu Arg Gly
625 630 635 640
Lys Arg Asp Gly Thr Phe Leu Val Arg Glu Ser Ser Lys Gln Gly Cys
645 650 655
Tyr Ala Cys Ser Val Val Val Asp Gly Glu Val Lys His Cys Val Ile
660 665 670
Asn Lys Thr Ala Thr Gly Tyr Gly Phe Ala Glu Pro Tyr Asn Leu Tyr
675 680 685
Ser Ser Leu Lys Glu Leu Val Leu His Tyr Gln His Thr Ser Leu Val
690 695 700
Gln His Asn Asp Ser Leu Asn Val Thr Leu Ala Tyr Pro Val Tyr Ala
705 710 715 720
Gln Gln Arg Arg
<210> 5
<211> 1077
<212> DNA
<213> 人工序列
<400> 5
atggcggcgg cggcggcggc gggcccggag atggtccgcg ggcaggtgtt cgacgtgggg 60
ccgcgctaca ctaatctctc gtacatcgga gaaggcgcct acggcatggt ttgttctgct 120
tatgataatc tcaacaaagt tcgagttgct atcaagaaaa tcagtccttt tgagcaccag 180
acctactgtc agagaaccct gagagagata aaaatcctac tgcgcttcag acatgagaac 240
atcatcggca tcaatgacat catccgggca ccaaccattg agcagatgaa agatgtatat 300
atagtacagg acctcatgga gacagatctt tacaagctct tgaagacaca gcacctcagc 360
aatgatcata tctgctattt tctttatcag atcctgagag gattaaagta tatacattca 420
gctaatgttc tgcaccgtga cctcaagcct tccaacctcc tgctgaacac cacttgtgat 480
ctcaagatct gtgactttgg ccttgcccgt gttgcagatc cagaccatga tcatacaggg 540
ttcttgacag agtatgtagc cacgcgttgg tacagagctc cagaaattat gttgaattcc 600
aagggttata ccaagtccat tgatatttgg tctgtgggct gcatcctggc agagatgcta 660
tccaacaggc ctatcttccc aggaaagcat taccttgacc agctgaatca catcctgggt 720
attcttggat ctccatcaca ggaagatctg aattgtataa taaatttaaa agctagaaac 780
tatttgcttt ctctcccgca caaaaataag gtgccgtgga acaggttgtt cccaaacgct 840
gactccaaag ctctggattt actggataaa atgttgacat ttaaccctca caagaggatt 900
gaagttgaac aggctctggc ccacccgtac ctggagcagt attatgaccc aagtgatgag 960
cccattgctg aagcaccatt caagtttgac atggagctgg acgacttacc taaggagaag 1020
ctcaaagaac tcatttttga agagactgct cgattccagc caggatacag atcttaa 1077
<210> 6
<211> 358
<212> PRT
<213> 人工序列
<400> 6
Met Ala Ala Ala Ala Ala Ala Gly Pro Glu Met Val Arg Gly Gln Val
1 5 10 15
Phe Asp Val Gly Pro Arg Tyr Thr Asn Leu Ser Tyr Ile Gly Glu Gly
20 25 30
Ala Tyr Gly Met Val Cys Ser Ala Tyr Asp Asn Leu Asn Lys Val Arg
35 40 45
Val Ala Ile Lys Lys Ile Ser Pro Phe Glu His Gln Thr Tyr Cys Gln
50 55 60
Arg Thr Leu Arg Glu Ile Lys Ile Leu Leu Arg Phe Arg His Glu Asn
65 70 75 80
Ile Ile Gly Ile Asn Asp Ile Ile Arg Ala Pro Thr Ile Glu Gln Met
85 90 95
Lys Asp Val Tyr Ile Val Gln Asp Leu Met Glu Thr Asp Leu Tyr Lys
100 105 110
Leu Leu Lys Thr Gln His Leu Ser Asn Asp His Ile Cys Tyr Phe Leu
115 120 125
Tyr Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser Ala Asn Val Leu
130 135 140
His Arg Asp Leu Lys Pro Ser Asn Leu Leu Leu Asn Thr Thr Cys Asp
145 150 155 160
Leu Lys Ile Cys Asp Phe Gly Leu Ala Arg Val Ala Asp Pro Asp His
165 170 175
Asp His Thr Gly Phe Leu Thr Glu Tyr Val Ala Thr Arg Trp Tyr Arg
180 185 190
Ala Pro Glu Ile Met Leu Asn Ser Lys Gly Tyr Thr Lys Ser Ile Asp
195 200 205
Ile Trp Ser Val Gly Cys Ile Leu Ala Glu Met Leu Ser Asn Arg Pro
210 215 220
Ile Phe Pro Gly Lys His Tyr Leu Asp Gln Leu Asn His Ile Leu Gly
225 230 235 240
Ile Leu Gly Ser Pro Ser Gln Glu Asp Leu Asn Cys Ile Ile Asn Leu
245 250 255
Lys Ala Arg Asn Tyr Leu Leu Ser Leu Pro His Lys Asn Lys Val Pro
260 265 270
Trp Asn Arg Leu Phe Pro Asn Ala Asp Ser Lys Ala Leu Asp Leu Leu
275 280 285
Asp Lys Met Leu Thr Phe Asn Pro His Lys Arg Ile Glu Val Glu Gln
290 295 300
Ala Leu Ala His Pro Tyr Leu Glu Gln Tyr Tyr Asp Pro Ser Asp Glu
305 310 315 320
Pro Ile Ala Glu Ala Pro Phe Lys Phe Asp Met Glu Leu Asp Asp Leu
325 330 335
Pro Lys Glu Lys Leu Lys Glu Leu Ile Phe Glu Glu Thr Ala Arg Phe
340 345 350
Gln Pro Gly Tyr Arg Ser
355
<210> 7
<211> 1143
<212> DNA
<213> 人工序列
<400> 7
atggcggcgg cggcggcggc tccggggggc gggggcgggg agcccagggg aactgctggg 60
gtcgtcccgg tggtccccgg ggaggtggag gtggtgaagg ggcagccatt cgacgtgggc 120
ccacgctaca cgcagctgca gtacatcggc gagggcgcgt acggcatggt cagctcagca 180
tatgaccacg tgcgcaagac cagagtggct atcaagaaga tcagcccctt cgagcatcaa 240
acctactgtc agcgcacgct gagagaaatc cagatcttgc tgcgattccg ccatgagaat 300
gtcataggca tccgagacat cctcagagca cccaccctgg aagccatgag agatgtttac 360
attgttcagg acctcatgga gacggacctg tacaagctgc taaagagcca gcagctgagc 420
aatgaccaca tctgctactt cctctaccag atcctccggg gcctcaagta catacactcg 480
gccaatgtgc tgcaccggga cctgaagccc tccaatctgc ttatcaacac cacctgcgac 540
cttaagatct gtgattttgg ccttgcccgg attgctgacc ctgagcacga ccacactggc 600
tttcttaccg agtatgtggc cacacgctgg taccgagccc cagagatcat gcttaactcc 660
aagggctaca ccaaatccat tgacatctgg tctgtgggct gcattctggc tgagatgctc 720
tccaaccggc ctatcttccc cggcaagcac tacctggacc agctcaacca cattctaggt 780
atactgggtt ccccatccca agaggaccta aattgtatca ttaacatgaa ggcccgaaac 840
tacctacagt ctctgccctc taaaaccaag gtggcttggg ccaagctttt tcccaaatct 900
gactccaaag ctcttgacct gctggaccgg atgttaacct ttaacccaaa caagcgcatc 960
acagtagagg aagcactggc tcacccttac ctggaacagt actatgatcc gacagatgaa 1020
ccagtggctg aggagccatt cacctttgac atggagctgg atgatctccc caaggagcgg 1080
ctgaaggagc tgatcttcca agagacagcc cgcttccagc caggggcacc agaggccccc 1140
taa 1143
<210> 8
<211> 380
<212> PRT
<213> 人工序列
<400> 8
Met Ala Ala Ala Ala Ala Ala Pro Gly Gly Gly Gly Gly Glu Pro Arg
1 5 10 15
Gly Thr Ala Gly Val Val Pro Val Val Pro Gly Glu Val Glu Val Val
20 25 30
Lys Gly Gln Pro Phe Asp Val Gly Pro Arg Tyr Thr Gln Leu Gln Tyr
35 40 45
Ile Gly Glu Gly Ala Tyr Gly Met Val Ser Ser Ala Tyr Asp His Val
50 55 60
Arg Lys Thr Arg Val Ala Ile Lys Lys Ile Ser Pro Phe Glu His Gln
65 70 75 80
Thr Tyr Cys Gln Arg Thr Leu Arg Glu Ile Gln Ile Leu Leu Arg Phe
85 90 95
Arg His Glu Asn Val Ile Gly Ile Arg Asp Ile Leu Arg Ala Pro Thr
100 105 110
Leu Glu Ala Met Arg Asp Val Tyr Ile Val Gln Asp Leu Met Glu Thr
115 120 125
Asp Leu Tyr Lys Leu Leu Lys Ser Gln Gln Leu Ser Asn Asp His Ile
130 135 140
Cys Tyr Phe Leu Tyr Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser
145 150 155 160
Ala Asn Val Leu His Arg Asp Leu Lys Pro Ser Asn Leu Leu Ile Asn
165 170 175
Thr Thr Cys Asp Leu Lys Ile Cys Asp Phe Gly Leu Ala Arg Ile Ala
180 185 190
Asp Pro Glu His Asp His Thr Gly Phe Leu Thr Glu Tyr Val Ala Thr
195 200 205
Arg Trp Tyr Arg Ala Pro Glu Ile Met Leu Asn Ser Lys Gly Tyr Thr
210 215 220
Lys Ser Ile Asp Ile Trp Ser Val Gly Cys Ile Leu Ala Glu Met Leu
225 230 235 240
Ser Asn Arg Pro Ile Phe Pro Gly Lys His Tyr Leu Asp Gln Leu Asn
245 250 255
His Ile Leu Gly Ile Leu Gly Ser Pro Ser Gln Glu Asp Leu Asn Cys
260 265 270
Ile Ile Asn Met Lys Ala Arg Asn Tyr Leu Gln Ser Leu Pro Ser Lys
275 280 285
Thr Lys Val Ala Trp Ala Lys Leu Phe Pro Lys Ser Asp Ser Lys Ala
290 295 300
Leu Asp Leu Leu Asp Arg Met Leu Thr Phe Asn Pro Asn Lys Arg Ile
305 310 315 320
Thr Val Glu Glu Ala Leu Ala His Pro Tyr Leu Glu Gln Tyr Tyr Asp
325 330 335
Pro Thr Asp Glu Pro Val Ala Glu Glu Pro Phe Thr Phe Asp Met Glu
340 345 350
Leu Asp Asp Leu Pro Lys Glu Arg Leu Lys Glu Leu Ile Phe Gln Glu
355 360 365
Thr Ala Arg Phe Gln Pro Gly Ala Pro Glu Ala Pro
370 375 380
<210> 9
<211> 22
<212> DNA
<213> 人工序列
<400> 9
ugagguagua guuuguacag uu 22
<210> 10
<211> 22
<212> DNA
<213> 人工序列
<400> 10
agagtttcct gggcatcaat aa 22
<210> 11
<211> 21
<212> DNA
<213> 人工序列
<400> 11
ctggaagtgt ggacttgtct t 21
<210> 12
<211> 21
<212> DNA
<213> 人工序列
<400> 12
ctggctttct gaccgagtat g 21
<210> 13
<211> 21
<212> DNA
<213> 人工序列
<400> 13
ggtgtagccc ttggagttaa g 21
<210> 14
<211> 20
<212> DNA
<213> 人工序列
<400> 14
gctggaggac aacgactatg 20
<210> 15
<211> 22
<212> DNA
<213> 人工序列
<400> 15
cttctcatgg tcctggttgt ag 22
<210> 16
<211> 24
<212> DNA
<213> 人工序列
<400> 16
gcttgaagac ctatgtgggt ataa 24
<210> 17
<211> 21
<212> DNA
<213> 人工序列
<400> 17
gggtggagaa aggaacagaa a 21
<210> 18
<211> 22
<212> DNA
<213> 人工序列
<400> 18
atcttaggga aggtcagcat tg 22
<210> 19
<211> 21
<212> DNA
<213> 人工序列
<400> 19
cacgagagtt caccagaatg t 21
<210> 20
<211> 20
<212> DNA
<213> 人工序列
<400> 20
cgcagtgagg tagtagtttg 20
<210> 21
<211> 27
<212> DNA
<213> 人工序列
<400> 21
caggtccagt tttttttttt ttttaac 27
<210> 22
<211> 20
<212> DNA
<213> 人工序列
<400> 22
actcttagcg gtggatcact 20
<210> 23
<211> 17
<212> DNA
<213> 人工序列
<400> 23
cgctcagaca ggcgtag 17
<210> 24
<211> 21
<212> DNA
<213> 人工序列
<400> 24
actcccattc ttccaccttt g 21
<210> 25
<211> 21
<212> DNA
<213> 人工序列
<400> 25
ccctgttgct gtagccatat t 21

Claims (4)

1.一种Col1a1蛋白在制备2型糖尿病生物标记物试剂中的应用,其特征在于,所述Col1a1蛋白的核苷酸序列如SEQ ID NO.1所示,氨基酸序列如SEQ ID NO.2所示。
2.根据权利要求1所述的应用,其特征在于,利用药物沉默let-7g-5p的表达水平以提高Col1a1的表达,改善空腹胰岛素、糖化血红蛋白、PI3K信号通路以及肠道内皮细胞稳态的相关基因MEK和ERK1/2的水平。
3.根据权利要求2所述的应用,其特征在于,所述药物包括浒苔寡糖。
4.根据权利要求3所述的应用,其特征在于,所述浒苔寡糖的制备方法包括以下步骤:按照1 g:40mL的料液比将绿藻粉和水混合,在60℃、45 kHZ、200 W条件下超声波辅助提取1-2 h;4500 rpm离心5-10分钟后取上清液,按照1:4的体积比加入 95%乙醇醇沉过夜;离心取沉淀置于50℃干燥后,1 g:100mL的比例将其溶于水,在溶液中加入蛋白酶使酶活200 U/mL,30-40℃温度条件下酶解2 h后,100℃灭酶活20 min取上清液,再透析48 h后浓缩冻干得浒苔多糖;1%浒苔多糖水溶解液,加入硫酸直至溶液浓度为0.05 mol/L,100℃水浴酸解1.5 h后,冷却后加1.0 mol/L NaOH将溶液调至中性,按1:1的体积比加入95%乙醇溶液醇沉8-12 h,后取上清液浓缩冻干,最终获得浒苔寡糖,特征产物的摩尔质量分布 <5000 Da。
CN202011561768.8A 2020-12-25 2020-12-25 Col1a1作为一种2型糖尿病的生物标志物及其应用 Active CN112553323B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011561768.8A CN112553323B (zh) 2020-12-25 2020-12-25 Col1a1作为一种2型糖尿病的生物标志物及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011561768.8A CN112553323B (zh) 2020-12-25 2020-12-25 Col1a1作为一种2型糖尿病的生物标志物及其应用

Publications (2)

Publication Number Publication Date
CN112553323A true CN112553323A (zh) 2021-03-26
CN112553323B CN112553323B (zh) 2022-05-13

Family

ID=75032687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011561768.8A Active CN112553323B (zh) 2020-12-25 2020-12-25 Col1a1作为一种2型糖尿病的生物标志物及其应用

Country Status (1)

Country Link
CN (1) CN112553323B (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069199A1 (en) * 2000-12-07 2003-04-10 Hanan Polansky Treatment methods based on microcompetition for a limiting GABP complex
CN101485343A (zh) * 2009-03-02 2009-07-22 中国海洋大学生物工程开发有限公司 浒苔活性成分的提取技术及浒苔海藻肥的制备方法
CN110302362A (zh) * 2018-03-20 2019-10-08 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106906278A (zh) * 2015-12-22 2017-06-30 复旦大学 预测ii型糖尿病心血管并发症风险的生物标记物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069199A1 (en) * 2000-12-07 2003-04-10 Hanan Polansky Treatment methods based on microcompetition for a limiting GABP complex
CN101485343A (zh) * 2009-03-02 2009-07-22 中国海洋大学生物工程开发有限公司 浒苔活性成分的提取技术及浒苔海藻肥的制备方法
CN110302362A (zh) * 2018-03-20 2019-10-08 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LV HAITAO等: "Selenylation Modification of Degraded Polysaccharide from Enteromorpha prolifera and Its Biological Activities", 《JOURNAL OF OCEAN UNIVERSITY OF CHINA》 *

Also Published As

Publication number Publication date
CN112553323B (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
US11098364B2 (en) Inhibiting the onset of gout
CN108330172A (zh) RT-qPCR检测树鼩SLC22A12/URAT1基因转录水平的方法
CN112553323B (zh) Col1a1作为一种2型糖尿病的生物标志物及其应用
CN107460241B (zh) 外泌体小分子rna在急性心肌梗死风险评估中的应用
RU2471193C2 (ru) Способ прогнозирования риска развития метаболитического синдрома у пациента с абдоминальным ожирением
CN114984222A (zh) Arl16蛋白激动剂在低氧下精子鞭毛多发形态异常中的应用
CN113604556A (zh) 一种用于确定glp-1受体激动剂疗效相关的基因snp检测试剂盒
CN108918891B (zh) 与人类蛋白nrf1相互作用的结核蛋白及其应用
CN111973612B (zh) 槲皮素-3-O-β-D-半乳糖苷在制备促进葡萄糖吸收药物方面的应用
CN111973580B (zh) 咖啡酸在制备促进葡萄糖吸收药物方面的应用
JP5748751B2 (ja) 糖尿病前症及び2型糖尿病における血清アミロイドの表現型比率
CN107586829A (zh) RT‑qPCR检测猕猴SLC22A12/URAT1基因转录水平的方法
CN113527423B (zh) 一种辅助治疗nafld的南极磷虾寡肽及其应用
JP7460196B2 (ja) Padi4を腫瘍マーカーとして製造した抗原、抗体及びその使用
CN107531756B (zh) 两种芋螺毒素肽、其制备方法及应用
CN107312836A (zh) 小分子RNAmiRNA‑146a‑5p在相关疾病风险诊断中的应用
CN116474103B (zh) Pdcd2l作为靶点在制备治疗炎症药物中的应用
CN116732176B (zh) 基因易位性肾细胞癌标记物组的应用
CN115125266B (zh) 一种重组载体、转化体及其在五环三萜类化合物糖基化修饰中的应用
JP5988238B2 (ja) 膜貫通型タンパク質の質量分析方法および比較定量解析方法
CN116747307A (zh) Periostin和Glucosyringic acid在治疗糖尿病心肌病中的应用
CN111647624A (zh) Tsab人源单克隆抗体重组载体、重组抗体及其制备方法
CN117512040A (zh) 一种大豆来源的类肠促胰岛素制备工艺
CN117343980A (zh) 一种具有抗血栓活性的汉麻仁多肽序列的筛选方法
CN115838398A (zh) 一种抑制α-葡萄糖苷酶活性的棘胸蛙多肽及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant